StreetInsider.com News Articles

FibroBiologics receives Australian patent acceptance for spinal disc treatment

Wed, 14 Oct 2026 08:32:35 -0400

FibroBiologics, Inc. (Nasdaq: FBLG) announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled "Cellular Blend for the Regeneration of Chondrocytes or Cartilage Type Cells."

The accepted application covers methods of generating chondrocytes or chondrocyte-like cells and repairing cartilage in degenerated spinal discs by delivering fibroblasts together with platelet rich plasma and components of the nucleus pulposus, including nucleus pulposus conditioned media. A Notice of Acceptance is the Australian equivalent of a notice of allowance and indicates that IP Australia has completed its examination. The patent application is expected to proceed to grant following

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

Wed, 14 Oct 2026 08:30:00 -0400

Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged Discs

HOUSTON, Oct. 14, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

Wed, 14 Oct 2026 08:30:00 -0400

Form POS AM FibroBiologics, Inc.

Tue, 13 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261013/27181347.html

Form POS AM FibroBiologics, Inc.

Tue, 13 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261013/27181299.html

Form D FibroBiologics, Inc.

Tue, 13 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261013/27176318.html

Form 8-K FibroBiologics, Inc. For: Oct 07

Thu, 08 Oct 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20261008/27167710.html

FibroBiologics files patent for cell-based GLP-1 peptide production

Wed, 07 Oct 2026 08:30:42 -0400

FibroBiologics, Inc. (Nasdaq: FBLG) has filed a U.S. patent application covering a cell-based technology designed to continuously produce therapeutic peptides, including GLP-1, GIP, and GLP-2, inside the body, the Houston-based clinical-stage biotechnology company said Oct. 7.

The application describes engineering living cells to form small three-dimensional structures called spheroids or organoids. Once administered to a patient, these structures are designed to continuously produce and release therapeutic peptides, potentially reducing the need for repeated injections or daily pills currently associated with GLP-1 medicines used for weight loss and diabetes.

The patent application covers cells engineered to secrete peptides at adjustable ratios, including dual

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

Wed, 07 Oct 2026 08:30:00 -0400

New approach proposes an alternative to repeated injections

HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that it has filed a U.S.

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

Wed, 07 Oct 2026 08:30:00 -0400

New approach proposes an alternative to repeated injections

FibroBiologics receives European patent for fibroblast treatment methods

Tue, 29 Sep 2026 08:32:44 -0400

FibroBiologics, Inc. (Nasdaq: FBLG) announced that the European Patent Office has granted European Patent No. 3568465, titled "Methods of Enhancing Fibroblast Therapeutic Activity," according to a company press release dated Sept. 29, 2026.

The patent covers methods of augmenting the efficacy of fibroblasts for cell and tissue regeneration by contacting the fibroblasts with platelet rich plasma and one or more cytokines, including fibroblast growth factor alpha (FGF-alpha) or fibroblast growth factor beta (FGF-beta). Additional claims are directed to angiogenesis and the regeneration of spinal discs.

The granted claims cover a range of fibroblast sources, including those obtained by biopsy and expanded in

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

Tue, 29 Sep 2026 08:30:00 -0400

Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration

HOUSTON, Sept. 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

Tue, 29 Sep 2026 08:30:00 -0400

Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Fri, 25 Sep 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 26, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, September 27, at 11:00 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.

Access the interviews in their entirety at:

Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Fri, 25 Sep 2026 09:00:00 -0400

Access the interviews in their entirety at:

Form 8-K FibroBiologics, Inc. For: Sep 17

Fri, 18 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260918/27080534.html

Form SCHEDULE 13D FibroBiologics, Inc. Filed by: Khoja Hamid

Thu, 17 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260917/27075725.html

FibroBiologics CSO buys $0.5M in stock via private placement

Thu, 17 Sep 2026 08:30:54 -0400

FibroBiologics, Inc. (Nasdaq: FBLG) announced the closing of a $0.5 million private placement on September 15, 2026, with Hamid Khoja, Ph.D., the company's Chief Scientific Officer, according to a press release.

Khoja purchased 298,508 shares of common stock along with warrants to purchase up to an additional 298,508 shares. Each share and accompanying warrant was sold at a combined price of $1.675, which reflects the Nasdaq Capital Market closing bid price of $1.55 per share on September 14, 2026, plus $0.125 per warrant.

The warrants carry an exercise price of $1.55 per share, are immediately exercisable, and expire five years from the

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

Thu, 17 Sep 2026 08:30:00 -0400

HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of a private placement on September 15, 2026, with Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, for the purchase of 298,508 shares of common stock and accompanying

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

Thu, 17 Sep 2026 08:30:00 -0400

Form D FibroBiologics, Inc.

Wed, 16 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260916/27066889.html

Form 4 FibroBiologics, Inc. For: Sep 15 Filed by: Khoja Hamid

Tue, 15 Sep 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260915/27066153.html

Form 8-K FibroBiologics, Inc. For: Sep 15

Tue, 15 Sep 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260915/27061048.html

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

Tue, 08 Sep 2026 09:00:00 -0400

Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblasts

Management to discuss the ongoing Phase 1/2 diabetic foot ulcer trial, upcoming clinical catalysts, broader pipeline opportunities, and an intellectual property portfolio of approximately 270 issued and pending patents

ORLANDO, FL / ACCESS Newswire / September 8, 2026 / RedChip Companies will host an investor webinar on Tuesday, September 22, 2026, at 4:15 p.m. ET with FibroBiologics, Inc. (NASDAQ:FBLG).

The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

Tue, 08 Sep 2026 09:00:00 -0400

Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblasts

ORLANDO, FL / ACCESS Newswire / September 8, 2026 / RedChip Companies will host an investor webinar on Tuesday, September 22, 2026, at 4:15 p.m. ET with FibroBiologics, Inc. (NASDAQ:FBLG).

The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an